Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | CASP3 | P42574 | 4/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.41 |
| ▸ | FABP7 | O15540 | 1/20 | 0.41 |
| ▸ | MDM4 | O15151 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9715037 | 0.81 | KMT2A (0.46) | KMT2ACASP3EPHX2FABP5FABP7 | |
| SCHEMBL15893669 | 0.81 | KMT2A (0.50) | KMT2ACASP3EPHX2FABP5FABP7 | |
| SCHEMBL16724665 | 0.79 | KMT2A (0.48) | KMT2ACASP3EPHX2 | |
| SCHEMBL2625076 | 0.78 | KMT2A (0.58) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL8451314 | 0.77 | KMT2A (0.57) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL13452269 | 0.76 | CASP3 (0.56) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL3269193 | 0.76 | CASP3 (0.56) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL5021152 | 0.76 | CASP3 (0.56) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL31068390 | 0.76 | CASP3 (0.56) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL29952701 | 0.76 | CASP3 (0.56) | KMT2ACASP3EPHX2MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150141324-A1 | STABLE PEPTIDE-BASED FURIN INHIBITORS | SOCPRA Sciences Sante et Humaines S.E.C. (CA) | 2015-05-21 | — | — | US | disclosed |
| US-20140206622-A1 | STABLE PEPTIDE-BASED PACE4 INHIBITORS | SOCPRA Sciences Sante et Humaines S.E.C. (CA) | 2014-07-24 | — | — | US | disclosed |
| WO-2013029180-A1 | STABLE PEPTIDE-BASED PACE4 INHIBITORS | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013029182-A1 | STABLE PEPTIDE-BASED FURIN INHIBITORS | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141324-A1 | STABLE PEPTIDE-BASED FURIN INHIBITORS | FURIN, PREP, VIP | KMT2A 3976/4885CASP3 644/4885EPHX2 2865/4885 |
| US-20140206622-A1 | STABLE PEPTIDE-BASED PACE4 INHIBITORS | FURIN, DNPEP, PRAP1 | KMT2A 3612/4885CASP3 1817/4885EPHX2 4687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.